Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Ovarian Neoplasms 2 Sarcoma 1 Radiation Pneumonitis 1 Pancreatic Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Inflammatory Breast Neoplasms 1 Glioblastoma 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Appendiceal Neoplasms 1

Interventions

Temozolomide 52 Radiotherapy 24 Bevacizumab 23 Radiation 10 Magnetic Resonance Spectroscopy 7 Lomustine 7 Carmustine 7 Radiosurgery 6 Surgical Procedures, Operative 5 Irinotecan 5 Aminolevulinic Acid 5 Radiotherapy, Intensity-Modulated 4 Nivolumab 4 Ipilimumab 4 Erlotinib Hydrochloride 4 Cilengitide 4 vocimagene amiretrorepvec 3 vitespin 3 sargramostim 3 poly ICLC 3 pembrolizumab 3 fluoromisonidazole 3 carmustine, poliferprosan 20 drug combination 3 Vorinostat 3 TPI-287 3 O(6)-benzylguanine 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Flucytosine 3 Dynamic Contrast Enhanced Magnetic Resonance Imaging 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Glioblastoma × nintedanib × Clear all

NCT01666600 2017-11-01

NOA-12: BIBF1120 and R-RT in Glioblastoma

University Hospital Heidelberg

Phase 1/2 Terminated

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡